Anti-YAP1 antibody [2F12]

• WB

Unknown

Western blot - Anti-YAP1 antibody [2F12] (AB56701)

YAP1 antibody (ab56701) at 1ug/lane + HeLa cell lysate at 25ug/lane.

This image was generated using the ascites version of the product.

All lanes:

Western blot - Anti-YAP1 antibody [2F12] (ab56701)

Predicted band size: 54 kDa

false

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-YAP1 antibody [2F12] (AB56701)

YAP1 antibody (ab56701) used in immunohistochemistry at 3ug/ml on formalin fixed and paraffin embedded human endometrium.

This image was generated using the ascites version of the product.

• WB

CiteAb

Western blot - Anti-YAP1 antibody [2F12] (AB56701)

Western Blotting using Anti-YAP1 antibody [2F12], ab56701. Publication image from Wu, Y. et al., 2020, Mol Cancer, 32106857. Legend direct from paper.

Ectopic expression of YAP and ALKBH5 regulates cell proliferation, invasion, migration, and EMT in NSCLC cells. (a) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays in the paired fresh NSCLC tumor cancer tissues (Tumor) and matched adjacent normal tissues (Normal) (left panel, n = 10; right panel, n = 30). (b) The expressions of YAP and ALKBH5 were analyzed by immunohistochemical (IHC) assay in the human lung cancer tissues and their normal adjacent lung tissues (n = 5). (c) The TCGA database indicated that YAP was higher but ALKBH5 was lower in tumor tissues than their normal tissues. (d) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR, qPCR and western blot assays in NSCLC cell lines and their control (normal) cell, BEAS-2B. (e) High expression of YAP (P = 0.00932) but low expression of ALKBH5 (P = 0.00545) were associated with worse prognosis for NSCLC patients. (f-j) A549 cells were transfected with indicated genes of YAP and ALKBH5. (f) The expressions of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays. (g) The cellular growth was analyzed by CCK8 assay. (h) The migration viability was analyzed by scratch assay. (i) The cellular invasion and migration growths were analyzed by transwell assay. (j) The expressions of E-cadherin and Vimentin were analyzed by RT-PCR and western blot assays. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups

false

• WB

CiteAb

Western blot - Anti-YAP1 antibody [2F12] (AB56701)

Western Blotting using Anti-YAP1 antibody [2F12], ab56701. Publication image from Wu, Y. et al., 2020, Mol Cancer, 32106857. Legend direct from paper.

ALKBH5 controls YAP expression by regulation m6A level in NSCLC. (a) Pie chart depicting the fraction of m6A peaks in 4 transcript segments. (b) Gene ontology (GO) enrichment analysis of tumor methylated genes in NSCLC patients. (c) The m6A levels of total and YAP were detected in human NSCLC cell lines determined by m6A methylation quantification kit and MeRIP-qPCR assay. (d) The total m6A levels were higher in 30 paired fresh NSCLC tumor cancer tissues (Tumor) than matched adjacent normal tissues (Normal) (n = 30). (e) The interaction between ALKBH5 and YAP pre-mRNA was detected by RIP. (f) The relative m6A level of YAP pre-mRNA was detected by MeRIP-qPCR in A549 cells. (g) Sequence motifs in m6A peaks identified by using m6Avar database from YAP CDS. (h) Putative m6A modification sites in the CDS sequence of YAP and synonymous mutations in the YAP CDS. (i) The interaction between ALKBH5 and YAP pre-mRNA was detected by RIP. (j) The relative of m6A level in YAP from co-expression of ALKBH5 and YAP WT/Muts# (left panel) or ALKBH5 and YAP Muts (right panel) in A549 and H1299 cells. (k) The relative mRNA levels of YAP were analyzed by RT-PCR. (l) The mRNA and protein levels of ALKBH5, YAP, CTGF and Cyr61 were detected in A549 cells. (m) The negative correlation between ALKBH5 and YAP was analyzed from TCGA database. (n) The expressions of wild type (ALKBH5 WT) and catalytic mutant (ALKBH5 KD) of ALKBH5 were analyzed by RT-PCR and western blot assays. (o) The relative of m6A level in YAP from ALKBH5 WT or KD transfected A549 cells. (p) The mRNA levels of ALKBH5, YAP, CTGF and Cyr61 were detected in A549 and H1299 cells. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups. ns, not significant

false

• WB

CiteAb

Western blot - Anti-YAP1 antibody [2F12] (AB56701)

Western Blotting using Anti-YAP1 antibody [2F12], ab56701. Publication image from Wu, Y. et al., 2020, Mol Cancer, 32106857. Legend direct from paper.

Ectopic expression of YAP and ALKBH5 regulates cell proliferation, invasion, migration, and EMT in NSCLC cells. (a) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays in the paired fresh NSCLC tumor cancer tissues (Tumor) and matched adjacent normal tissues (Normal) (left panel, n = 10; right panel, n = 30). (b) The expressions of YAP and ALKBH5 were analyzed by immunohistochemical (IHC) assay in the human lung cancer tissues and their normal adjacent lung tissues (n = 5). (c) The TCGA database indicated that YAP was higher but ALKBH5 was lower in tumor tissues than their normal tissues. (d) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR, qPCR and western blot assays in NSCLC cell lines and their control (normal) cell, BEAS-2B. (e) High expression of YAP (P = 0.00932) but low expression of ALKBH5 (P = 0.00545) were associated with worse prognosis for NSCLC patients. (f-j) A549 cells were transfected with indicated genes of YAP and ALKBH5. (f) The expressions of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays. (g) The cellular growth was analyzed by CCK8 assay. (h) The migration viability was analyzed by scratch assay. (i) The cellular invasion and migration growths were analyzed by transwell assay. (j) The expressions of E-cadherin and Vimentin were analyzed by RT-PCR and western blot assays. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups

false

• WB

CiteAb

Western blot - Anti-YAP1 antibody [2F12] (AB56701)

Western Blotting using Anti-YAP1 antibody [2F12], ab56701. Publication image from Wu, Y. et al., 2020, Mol Cancer, 32106857. Legend direct from paper.

Ectopic expression of YAP and ALKBH5 regulates cell proliferation, invasion, migration, and EMT in NSCLC cells. (a) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays in the paired fresh NSCLC tumor cancer tissues (Tumor) and matched adjacent normal tissues (Normal) (left panel, n = 10; right panel, n = 30). (b) The expressions of YAP and ALKBH5 were analyzed by immunohistochemical (IHC) assay in the human lung cancer tissues and their normal adjacent lung tissues (n = 5). (c) The TCGA database indicated that YAP was higher but ALKBH5 was lower in tumor tissues than their normal tissues. (d) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR, qPCR and western blot assays in NSCLC cell lines and their control (normal) cell, BEAS-2B. (e) High expression of YAP (P = 0.00932) but low expression of ALKBH5 (P = 0.00545) were associated with worse prognosis for NSCLC patients. (f-j) A549 cells were transfected with indicated genes of YAP and ALKBH5. (f) The expressions of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays. (g) The cellular growth was analyzed by CCK8 assay. (h) The migration viability was analyzed by scratch assay. (i) The cellular invasion and migration growths were analyzed by transwell assay. (j) The expressions of E-cadherin and Vimentin were analyzed by RT-PCR and western blot assays. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups

false

• WB

CiteAb

Western blot - Anti-YAP1 antibody [2F12] (AB56701)

Western Blotting using Anti-YAP1 antibody [2F12], ab56701. Publication image from Wu, Y. et al., 2020, Mol Cancer, 32106857. Legend direct from paper.

Ectopic expression of YAP and ALKBH5 regulates cell proliferation, invasion, migration, and EMT in NSCLC cells. (a) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays in the paired fresh NSCLC tumor cancer tissues (Tumor) and matched adjacent normal tissues (Normal) (left panel, n = 10; right panel, n = 30). (b) The expressions of YAP and ALKBH5 were analyzed by immunohistochemical (IHC) assay in the human lung cancer tissues and their normal adjacent lung tissues (n = 5). (c) The TCGA database indicated that YAP was higher but ALKBH5 was lower in tumor tissues than their normal tissues. (d) The mRNA and protein levels of YAP and ALKBH5 were analyzed by RT-PCR, qPCR and western blot assays in NSCLC cell lines and their control (normal) cell, BEAS-2B. (e) High expression of YAP (P = 0.00932) but low expression of ALKBH5 (P = 0.00545) were associated with worse prognosis for NSCLC patients. (f-j) A549 cells were transfected with indicated genes of YAP and ALKBH5. (f) The expressions of YAP and ALKBH5 were analyzed by RT-PCR and western blot assays. (g) The cellular growth was analyzed by CCK8 assay. (h) The migration viability was analyzed by scratch assay. (i) The cellular invasion and migration growths were analyzed by transwell assay. (j) The expressions of E-cadherin and Vimentin were analyzed by RT-PCR and western blot assays. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups

false